Fluoxetine (FLX) is an antidepressant worldwide pres
cribed throughout life stages, in
cluding pregnan
cy and breastfeeding. Out of pregnan
cy, the
combination of FLX with fish oil (FO) and foli
c a
cid (FA) is
carried to enhan
ce the therapeuti
c a
ctivity and redu
ce the side effe
cts of the antidepressant. During pregnan
cy, FO and FA have been used to promote fetal development, and redu
ce, in mother, the risk of gestational and post-pregnan
cy depression. To evaluate if
maternal exposure during pregnan
cy and la
ctation to FLX asso
ciated with FO or FA would prevent the antidepressant side effe
cts in aorta rea
ctivity and nitri
c oxide metabolites (NOx) plasmati
c levels. We also sought to understand, in female offspring, the vas
cular effe
cts of intrauterine and la
ctation exposure to FO and FA monotherapy.
c_2">Main methods
Wistar rats were treated with water (control group), FLX (5 mg/kg/day), FO (1.3 g/kg/day), FA (3 mg/kg/day), FLX + FO and FLX + FA, throughout pregnancy and lactation. On adulthood, in female offspring were evaluated the vascular reactivity to phenylephrine (Phe), the NOx and homocysteine (HCY) plasmatic levels.
c_3">Key findings
The developmental exposure to the associations of FO or FA with FLX did not correct the aortic hyporreactivity and increased NOx levels induced by intrauterine and lactation exposure to FLX. Also, isolated exposure to FO and FA did not interfere with Phe-induced aortic contraction and neither interferes with NOx and HCY plasmatic levels.
c_4">Significance
The developmental exposure to FO and FA was safe for vascular function of female offspring but did not prevent the vascular effects of FLX-exposure.